Can the in-hospital mortality gap between STEMI patients with and without diabetes mellitus be reduced? The cardio-renal hypothesis.

[1]  S. Del Prato,et al.  Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor? , 2020, Diabetes research and clinical practice.

[2]  J. McMurray,et al.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. , 2019, The lancet. Diabetes & endocrinology.

[3]  F. Veglia,et al.  Reduced Cardio-Renal Function Accounts for Most of the In-Hospital Morbidity and Mortality Risk Among Patients With Type 2 Diabetes Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction , 2019, Diabetes Care.

[4]  Marc P. Bonaca,et al.  Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials , 2019, Circulation.

[5]  Alexander M. Kiel,et al.  Inhibition of sodium–glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization , 2019, Basic Research in Cardiology.

[6]  M. Mizuno,et al.  Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[7]  F. Veglia,et al.  Prognostic Value of the Acute-to-Chronic Glycemic Ratio at Admission in Acute Myocardial Infarction: A Prospective Study , 2018, Diabetes Care.

[8]  C. Stein,et al.  Structural Equation Modeling. , 2017, Methods in molecular biology.

[9]  J. Spertus,et al.  Predicting Adverse Outcomes After Myocardial Infarction Among Patients With Diabetes Mellitus , 2016, Circulation. Cardiovascular Quality and Outcomes.

[10]  W. Laskey,et al.  In‐Hospital Mortality Among Patients With Type 2 Diabetes Mellitus and Acute Myocardial Infarction: Results From the National Inpatient Sample, 2000–2010 , 2014, Journal of the American Heart Association.

[11]  Kevin P. High,et al.  Diabetes and Cardiovascular Disease in Older Adults: Current Status and Future Directions , 2014, Diabetes.

[12]  Linda Valeri,et al.  Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. , 2013, Psychological methods.

[13]  N. Marx,et al.  Cardiovascular disease and diabetes: the vulnerable patient , 2012 .

[14]  J. Holst,et al.  Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. , 2012, European heart journal.

[15]  G. Fonarow,et al.  Recent US Patterns and Predictors of Prevalent Diabetes among Acute Myocardial Infarction Patients , 2011, Cardiology research and practice.

[16]  R. Henkelman,et al.  GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice , 2009, Diabetes.

[17]  R. Shannon,et al.  Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion , 2004, Circulation.

[18]  W. Dudley,et al.  SPSS and SAS Programming for the Testing of Mediation Models , 2004, Nursing research.

[19]  S. Haffner.  Coronary heart disease in patients with diabetes. , 2000, The New England journal of medicine.